EP1312385A1 - Dispositif medical intraluminal - Google Patents
Dispositif medical intraluminal Download PDFInfo
- Publication number
- EP1312385A1 EP1312385A1 EP02292870A EP02292870A EP1312385A1 EP 1312385 A1 EP1312385 A1 EP 1312385A1 EP 02292870 A EP02292870 A EP 02292870A EP 02292870 A EP02292870 A EP 02292870A EP 1312385 A1 EP1312385 A1 EP 1312385A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- medical device
- hydrophilic
- wetting agent
- hydrophilic substance
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
- A61L29/085—Macromolecular materials
Definitions
- the invention relates to the field of medical devices, and more particularly catheters, or medical probes, adapted to be introduced into a body duct.
- the intraluminal ducts where circulates a fluid are particularly concerned.
- Urinary or anal catheters are specially targeted.
- the present invention also addresses the problem of controlling evaporation of the wetting agent once the medical device has been treated, and / or the problem of untimely flow of packaging (or even said the devices themselves when wetted by the wetting agent).
- the solution proposed by the invention consists in particular in that the hydrophilic zone comprises, when dry, a second hydrophilic substance constituting a wetting agent retention agent within the area hydrophilic, to limit the evaporation in air of this wetting agent outside of the medical device and / or prevent said wetting agent from leaking inadvertently (like a liquid; especially water), once the treated area.
- zone must be understood as all or part of the medical device to be introduced into the body conduit concerned and in particular as all or part of the thickness of this device.
- the second hydrophilic substance will be chosen as totally compatible (chemically in particular) with the first substance hydrophilic to constitute what the invention defines as the retention of the wetting agent which permeates it, once the hydrophilic zone treated by contact with this wetting agent.
- the second hydrophilic substance remains in contact with the medical device where it was applied, within the hydrophilic zone, in being permanently “functionally” linked to the first substance hydrophilic throughout the duration of use of the medical device in the conduit where this device was previously introduced, and even elsewhere in the packaging where this device was previously conditioned, therefore that the device is covered with its two hydrophilic, dry substances, from its manufacture, and is thus thus conditioned.
- the solution of the invention vis-à-vis the problem of evaporation is in this case in the constitution of the medical device and not in that of the packaging.
- the invention also addresses the problem of nature of the wetting agent retention agent making it possible to avoid as much as possible the presence of liquid or a fountain bath in packaging, in particular to avoid any unexpected leakage during deconditioning of the product, when the packaging is opened for use of the device.
- a feature of the invention advises that the agent of wetting has the consistency of a gel, so that the treatment of the area hydrophilicity of the medical device by the wetting agent may consist of coating this area (soaking, vacuum distribution, etc.) with a "solid” or “semi-solid” compound, in particular viscous, much more viscous than a liquid.
- a wetting gel (having a retention capacity of an aqueous compound) can thus cover the area externally hydrophilic of the medical device.
- another characteristic of the invention also consists in that the medical device (including the area hydrophilic is then impregnated with the wetting agent), remains in its packaging, after this treatment and during its subsequent duration of packaging in this packaging, without soaking in any liquid.
- Another problem which the invention addresses concerns the risks to which the patient could be exposed, in the event that despite all the precautions taken, the friction between the medical device treated and the this patient's bodily conduct would nevertheless prove to be too important.
- the wetting agent retention agent includes in its composition a lubricant that limits friction against the implantation duct compared to what this friction would be, under the same conditions, without lubricant.
- the glycerin is advisable for its qualities both lubricating and retention aqueous solutions, as well as for the possibility offered by a inexpensive implementation, glycerin also being a product medically commonly used and of good tolerance.
- the hydrophilic zone lubricating or not, include between about 59.5% and 10% aqueous compound (to within 2%), as an agent wetting and at least about 40% of second hydrophilic substance.
- the medical device may in particular comprise a central body made of a hydrophobic or hydrophilic polymer coated with a first thin hydrophilic layer (typically containing polyvinyl pirolidone - PVP-grafted as active compound on some microns thick), this first layer being covered with a second moistened hydrophilic layer, of thickness greater than the first.
- a first thin hydrophilic layer typically containing polyvinyl pirolidone - PVP-grafted as active compound on some microns thick
- a second moistened hydrophilic layer of thickness greater than the first.
- PVP-grafted ensures effective maintenance of the first hydrophilic layer on the central body of the probe and the second layer coating used in particular for the humidification of the first achieves lubrication limiting inconvenience for the user and the possible associated bodily risks, when the probe is wet, with a suitable outfit over time.
- any probe must be kept sterile in its packaging.
- EP-A-0 935 478 teaches to use gas-tight packaging (especially aluminum foil), which prevents gas sterilization (typically ethylene oxide) and directs typically toward radiation sterilization.
- the invention aims to limit the costs of the step of sterilization, taking advantage of the presence of the liquid retention agent mooring.
- treating the hydrophilic area of the probe with the wetting agent is very advantageously carried out before, or during the conditioning of the probe in its packaging, which allows to obtain a ready-to-use product: the user does not have to wait for a certain "wetting delay" of the probe to use it, contrary to what is example provided in EP-A-0 815 037.
- Figure 1 we see a urinary catheter 1, as an illustration non-limiting of a medical device according to the invention.
- a lateral arm 7 for urine outlet is connects to catheter 3, proximal side.
- the urinary catheter, and in particular the catheter 3, could in particular be carried out as described in CN-A-11 06 744 (see pages 2 and 3, claims 1 to 14).
- the entire structure of the catheter could be made dry (i.e. not treated with the wetting agent) of a compound comprising in particular between 10% and 30% by weight of alcohol polyvinyl (first hydrophilic constituent), from 30% to 50% by weight of water, from 5% to 15% by weight of sulfoxide and from 2% to 8% by weight of alkane linear C10 - C55, as well as between 10% and 30% by weight of a second hydrophilic constituent having more particularly the function of retaining the polyvinyl alcohol wetting agent.
- a compound comprising in particular between 10% and 30% by weight of alcohol polyvinyl (first hydrophilic constituent), from 30% to 50% by weight of water, from 5% to 15% by weight of sulfoxide and from 2% to 8% by weight of alkane linear C10 - C55, as well as between 10% and 30% by weight of a second hydro
- a hydrophilic structure suitable for have good wetting agent retention capacity and good slip performance (i.e., a low coefficient of friction) following the contacting of this structure hydrophilic with wetting agent (e.g. water or a solution isotonic sodium chloride and sterile water) activating in especially the polyvinyl alcohol compound, this prior to use of the probe into the patient's body duct.
- wetting agent e.g. water or a solution isotonic sodium chloride and sterile water
- An elastomeric material with enhanced water retention capacity could also be employed.
- the result would be a probe with a coefficient of friction and lower wetting agent retention capacity than a dry probe not treated with its wetting agent, and weaker also a hydrophobic probe (at least on the outer surface) lubricated for example with paraffin or glycerin.
- the material used can in particular be PVC (polychloride of vinyl) or elastomer, or polyurethane.
- this substrate is applied a layer of polymer or hydrophilic resin with great compatibility with the tissues of the human body and therefore suitable for soaking up a wetting solution, if it is brought into contact with such a solution.
- hydrophilic resins capable of constituting layer 9 in other words, the first hydrophilic constituent of the probe
- PVP or HEMA hydroxyethylmethacrylate
- Other compounds can be found in column 4, line 6 to column 5, line 42 of JP-B-55 12 265 (corresponding to JP-A-49-13 2888).
- such a liquid wetting agent is water or a aqueous solution.
- the invention recommends the second solution for obtaining a probe ready to use as soon as the package is opened, but with the possibility of additional consisting in that, in the packaging, the probe may not soak in no liquid, and in particular not in liquid wetting (or swelling) as is the case in EP-B-0 935 478.
- the surface hydrophilic 9 (and more previously the first hydrophilic constituent above) with a non-liquid agent, in particular very viscous, having preferably a gelatinous consistency and comprising a liquid of wetting (especially water or an aqueous compound) and an agent (called also second hydrophilic constituent) of retention of this liquid wetting limiting air evaporation of the wetting liquid from the probe.
- a non-liquid agent in particular very viscous, having preferably a gelatinous consistency and comprising a liquid of wetting (especially water or an aqueous compound) and an agent (called also second hydrophilic constituent) of retention of this liquid wetting limiting air evaporation of the wetting liquid from the probe.
- the wetting liquid of the first hydrophilic constituent (still dry) of the probe will be retained around the catheter, in contact with it.
- a wetting agent which can act as a wetting agent swelling vis-à-vis a suitable hydrophilic substance
- a aqueous solution aqueous solution, isotonic aqueous solution, aqueous solution isotonic sodium chloride and sterile water.
- the hydrophilic coating 9 is in contact and covered by an outer layer 11 whose function is therefore to wet the hydrophilic coating 9, while promoting the retention of the wetting on the probe itself. With the consistency of a gel, such layer 11 can easily be spread and thus externally coat the first hydrophilic layer 9.
- the outer layer 11 defines the surface outside of the catheter and contains both a wetting liquid from the coating 9 (typically water) and the retention agent for this liquid wetting.
- a wetting liquid from the coating 9 typically water
- the retention agent for this liquid wetting typically water
- the agent for retaining the wetting liquid will be preferably a lubricant therefore having a hygroscopic capacity.
- any lubricant Like any lubricant, it will have the function of limiting the friction (especially in contact with a body duct), in particular assuming that the decrease in the coefficient of friction of the probe induced by wetting would not be considered sufficient at the time of the use of this probe.
- a substance that is both lubricating and retaining the Wetting of the first hydrophilic constituent is glycerin. Although less we could try to use other glycols or tryols alphatic with a lubricating capacity and a molar mass of less than 200.
- the wetting fluid retention agent by its hygroscopic power, keeps the hydrophilic layer 9 hydrated, by reducing water evaporation.
- the coating of the hydrophilic layer 9 with a gel capable of forming the layer 11 of FIG. 2 can be obtained by dipping the coating 9 (and therefore catheter 30) in a bath of this gel.
- Another technique ensuring a uniform distribution of the wetting agent around layer 9, for example using a vacuum in a sheath where was previously inserted the probe and which would contain a certain amount of said gel, can also be used.
- the thickness of the layer 9 can be a few microns, that of the gelled layer 11 can be 3 to 10 times greater.
- coating layer 9 with the layer 11 should preferably be done before or at the time of packaging the probe in a package, such as package 13 of the Figure 3, so that during its entire shelf life in sterile packaging 13 (typically between a few months and several years), probe 1 will be externally impregnated with the wetting and, thus, it will be enough to open the package 13 to use immediately this probe, without having to wait a while then impregnation of the hydrophilic surface.
- the probe 1 is, inside the packaging 13, housed in a tubular sheath 15. In the present case, all of the length of catheter 3 extends inside the sheath 15; only the end 10 of the spring probe.
- the catheter 3 therefore does not soak in any liquid, just as no liquid is contained in the inner pocket 17 of the packaging where the sheath is placed 15.
- the package 13 can be closed.
- At least one of the walls of the packaging is preferably permeable to gas, and in particular to the gas used for sterilization (such as ethylene oxide).
- the package 13 is unsealed. If the probe 1 has been slid into the sheath 15, it is extracted therefrom and can be used. In the case where it has been pre-impregnated with the wetting liquid, the user can immediately introduce it into the corresponding body duct.
- the probe catheter 3 ' is a flexible biocompatible tube which can be manufactured like catheter 3, i.e. to be at least externally hydrophilic and wettable by a wetting agent, before use.
- the catheter 3 ' is attached at one end to a flexible pouch of recovery / storage 21 with which it is in fluid communication 23.
- the 3 'catheter is placed, for sterile packaging, in a flexible sheath 15 ′ which may have the characteristics of sheath 15.
- the sheath 15 ' is elongated along the axis of the catheter and is fixed to the pocket 21.
- the sheath 15 ′ is closed by a tearable zone 25, opposite the pocket 21.
- the 15 'flexible sheath is itself packaged in an outer pocket 13 'which can be structurally identical to packaging 13.
- the catheter 3 'thus conditioned is sterilizable with gas (walls of the "conditioning bags" which then surround it permeable).
- probe 1 can be used as a probe (or catheter) anal, especially if a "tight" slip (little play) is achieve.
- the trocars the probes sub-pubic and catheters (especially angioplasty) equipped with a inflatable balloon in a vessel.
- a vessel In the latter it could be only the membrane of the balloon which would be designed as in the invention. Only some elements, or parts thereof, of an intraluminal plus medical device complete could therefore be designed as provided in the invention.
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials For Medical Uses (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Surgical Instruments (AREA)
- Electrotherapy Devices (AREA)
- External Artificial Organs (AREA)
Abstract
Description
- une première couche comprenant une proportion nettement plus importante de première substance hydrophile que de deuxième substance hydrophile, et
- une deuxième couche, autour de la première, comprenant une proportion nettement plus importante de deuxième substance hydrophile que de première substance hydrophile.
- de préparer la sonde pour qu'à l'intérieur de l'emballage la zone hydrophile comprenne une deuxième substance hydrophile constituant un agent de rétention de l'agent de mouillage, en vue en particulier de limiter l'évaporation à l'air de cet agent de mouillage hors de la sonde, une fois la zone traitée,
- et de stériliser dans l'emballage la sonde ainsi conditionnée, par vaporisation gazeuse à travers une paroi perméable au gaz de l'emballage.
- que l'étape de préparation de la sonde comprenne l'enduction d'une couche comprenant la deuxième substance hydrophile autour d'une couche sous-jacente comprenant la première substance hydrophile,
- et/ou que lors de l'étape de préparation de la sonde, on mette en contact la première substance hydrophile avec à la fois la deuxième substance hydrophile et l'agent de mouillage.
- la figure 1 montre schématiquement une sonde conforme à l'invention, dans son état prêt à l'emploi,
- la figure 2 montre une coupe longitudinale agrandie de la sonde à l'endroit repéré II sur la figure 1,
- la figure 3 montre la sonde dans un emballage approprié pour son stockage (qui peut être de longue durée), et
- la figure 4 montre une variante de réalisation.
- soit de conditionner la sonde avec son revêtement hydrophile déjà mouillé par un liquide de gonflement dans son emballage, de sorte que la sonde peut être directement utilisée au moment de l'ouverture de l'emballage (voir EP-B-0 935 478),
- soit de mouiller la surface hydrophile juste avant l'utilisation de la sonde (comme par exemple dans US-A-3 967 728 ou dans EP-B-0 815 037 où une sonde à revêtement hydrophile est conditionnée sèche dans son emballage puis mouillée au moment de l'ouverture de cet emballage, de sorte qu'il faut attendre quelques instants avant de pouvoir utiliser la sonde, une fois l'emballage ouvert ; typiquement de l'ordre de 30 s).
Claims (16)
- Dispositif médical intraluminal adapté pour être introduit dans un conduit corporel, le dispositif médical présentant au moins localement une zone hydrophile (3, 3') comprenant une première substance hydrophile et présentant extérieurement un faible coefficient de frottement consécutivement à un traitement de ladite zone avec un agent de mouillage de ladite première substance hydrophile, préalablement à l'utilisation de la sonde, caractérisé en ce que la zone hydrophile (3) comprend à sec une deuxième substance hydrophile constituant un agent de rétention de l'agent de mouillage au sein de la zone hydrophile, pour limiter l'évaporation à l'air de cet agent de mouillage hors du dispositif médical et/ou pour éviter audit agent de mouillage de couler, comme de l'eau, une fois la zone traitée.
- Dispositif médical selon la revendication 1, caractérisé en ce que la zone hydrophile (3) comprend :une première couche (9) comprenant une proportion nettement plus importante de première substance hydrophile que de deuxième substance hydrophile, etune deuxième couche (11), autour de la première, comprenant une proportion nettement plus importante de deuxième substance hydrophile que de première substance hydrophile.
- Dispositif médical selon l'une quelconque des revendications précédentes, caractérisé en ce que l'agent de rétention de l'agent de mouillage est un lubrifiant hygroscopique qui limite les frottements.
- Dispositif médical selon l'une quelconque des revendications précédentes, caractérisé en ce que l'agent de rétention de l'agent de mouillage comprend de la glycérine.
- Dispositif médical selon l'une quelconque des revendications précédentes, caractérisé en ce que la première substance hydrophile est adaptée pour gonfler en présence de l'agent de mouillage, lequel consiste alors en un agent de gonflement.
- Dispositif médical selon l'une quelconque des revendications précédentes, caractérisé en ce que la sonde comprend un substrat central (30) recouvert de ladite zone hydrophile.
- Dispositif médical selon l'une quelconque des revendications précédentes, caractérisé en ce que la deuxième substance hydrophile présente une consistance gélatineuse.
- Dispositif médical selon l'une quelconque des revendications précédentes, caractérisé en ce que la zone hydrophile comprend au moins 40 % de deuxième substance hydrophile et entre 59,5% et 10 % de composé aqueux, en particulier de l'eau, en tant qu'agent de mouillage.
- Dispositif médical selon la revendication 4 ou la revendication 8, caractérisé en ce qu'elle comprend entre 70 % et 90 % de glycérine en tant qu'agent de rétention de l'agent de mouillage.
- Ensemble comprenant :un dispositif médical selon l'une quelconque des revendications précédentes, le dispositif consistant de préférence en une sonde,un emballage (13) dans lequel le dispositif est conditionné mouillé, imprégné par son agent de mouillage, préalablement ou lors de son conditionnement dans l'emballage,et après imprégnation, pendant sa durée ultérieure de maintien dans l'emballage, le dispositif médical demeure dans son emballage sans y tremper dans aucun liquide.
- Ensemble selon la revendication 10, caractérisé en ce que, dans un emballage, le dispositif médical est recouvert d'un gel de mouillage, à l'endroit de sa zone hydrophile (3), ce gel constituant l'agent de rétention de l'agent de mouillage.
- Procédé de préparation d'un dispositif médical intraluminal, tel en particulier qu'une sonde, dans un emballage, dans lequel procédé:on obtient un dispositif médical présentant au moins localement une zone hydrophile (3) comprenant une première substance hydrophile et présentant extérieurement un faible coefficient de frottement consécutivement à un traitement de ladite zone avec un agent de mouillage de ladite première substance hydrophile, préalablement à l'utilisation du dispositif médical,on conditionne ce dispositif médical dans un emballage (13),avant ou lors de l'étape de conditionnement, on traite le dispositif médical avec l'agent de mouillage pour qu'il s'en imprègne,et on stérilise l'intérieur de l'emballage,on prépare le dispositif médical pour qu'à l'intérieur de l'emballage (13) la zone hydrophile (3) comprenne une deuxième substance hydrophile constituant un agent de rétention de l'agent de mouillage, pour limiter l'évaporation à l'air de cet agent de mouillage hors du dispositif médical, une fois la zone traitée,et l'étape de stérilisation comprend une stérilisation gazeuse, à travers au moins une paroi (19) de l'emballage qui est perméable au gaz.
- Procédé selon la revendication 12, caractérisé en ce que l'étape de préparation du dispositif médical comprend l'enduction d'une couche (11) comprenant la deuxième substance hydrophile autour d'une couche sous-jacente (9) comprenant la première substance hydrophile.
- Procédé selon la revendication 12 ou la revendication 13, caractérisé en ce que lors de l'étape de préparation du dispositif médical, on met en contact la première substance hydrophile avec à la fois la deuxième substance hydrophile et l'agent de mouillage.
- Procédé selon l'une quelconque des revendications 12 à 14, caractérisé en ce que, lors de l'étape de préparation du dispositif médical, on enduit extérieurement sa zone hydrophile (3) avec un gel de mouillage (11) contenant une quantité de deuxième substance hydrophile et d'agent de mouillage.
- Utilisation du dispositif médical selon l'une quelconque des revendications 1 à 9 en tant que sonde urinaire ou sonde annale.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0114988 | 2001-11-20 | ||
FR0114988A FR2832314B1 (fr) | 2001-11-20 | 2001-11-20 | Sonde medicale intraluminale |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1312385A1 true EP1312385A1 (fr) | 2003-05-21 |
EP1312385B1 EP1312385B1 (fr) | 2006-02-01 |
EP1312385B2 EP1312385B2 (fr) | 2009-10-21 |
Family
ID=8869576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02292870A Expired - Lifetime EP1312385B2 (fr) | 2001-11-20 | 2002-11-19 | Dispositif medical intraluminal |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1312385B2 (fr) |
AT (1) | ATE316803T1 (fr) |
DE (1) | DE60208989T3 (fr) |
DK (1) | DK1312385T4 (fr) |
ES (1) | ES2255600T5 (fr) |
FR (1) | FR2832314B1 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111163816A (zh) * | 2017-05-19 | 2020-05-15 | 珀雷克斯公司 | 具有亲水性烧结多孔塑料或亲水性多孔纤维空气阻止过滤器的输注装置 |
EP3570899B1 (fr) | 2017-01-20 | 2021-03-10 | Hollister Incorporated | Procédés de stérilisation d'un dispositif médical à revêtement hydrophile |
US11167107B2 (en) | 2016-09-27 | 2021-11-09 | Coloplast A/S | Hydrated catheter with sleeve |
US11771584B2 (en) | 2018-12-20 | 2023-10-03 | Coloplast A/S | Urine collecting bag |
US11969558B2 (en) | 2018-07-20 | 2024-04-30 | Coloplast A/S | Intermittent urinary catheter assembly |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6810061B2 (ja) | 2015-06-26 | 2021-01-06 | コロプラスト アクティーゼルスカブ | 導尿カテーテルアセンブリ |
US11951219B2 (en) | 2017-01-20 | 2024-04-09 | Hollister Incorporated | Method for sterilizing a substrate having a hydrophilic coating and sterilized substrates |
ES2884077T3 (es) | 2017-02-21 | 2021-12-10 | Hollister Inc | Geles activados por radiación que liberan fluidos y conjuntos que contienen los mismos |
WO2019222644A1 (fr) | 2018-05-17 | 2019-11-21 | Hollister Incorporated | Procédés de fabrication d'ensembles de cathéters hydrophiles à manchon |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5001009A (en) * | 1987-09-02 | 1991-03-19 | Sterilization Technical Services, Inc. | Lubricious hydrophilic composite coated on substrates |
US5509899A (en) * | 1994-09-22 | 1996-04-23 | Boston Scientific Corp. | Medical device with lubricious coating |
WO1996030277A1 (fr) * | 1995-03-29 | 1996-10-03 | Coloplast A/S | Applicateur et procede permettant une introduction sterile d'un catheter medical |
WO1998011932A1 (fr) * | 1996-09-18 | 1998-03-26 | Coloplast A/S | Ensemble catheter urinaire pret a l'emploi |
WO1998019729A1 (fr) * | 1996-11-01 | 1998-05-14 | Coloplast A/S | Ensemble sonde urinaire muni d'une sonde prete a l'emploi |
GB2319507A (en) * | 1996-11-21 | 1998-05-27 | Rusch Manufacturing | Packaged catheter with lubricant-activating liquid |
US5800412A (en) * | 1996-10-10 | 1998-09-01 | Sts Biopolymers, Inc. | Hydrophilic coatings with hydrating agents |
WO2000067816A1 (fr) * | 1999-05-07 | 2000-11-16 | Scimed Life Systems, Inc. | Revetement lubrifiant comprenant un agent anti-adherent pour appareils medicaux |
WO2000071181A1 (fr) * | 1999-05-21 | 2000-11-30 | Scimed Life Systems, Inc. | Revetement lubrifiant pour instruments medicaux |
-
2001
- 2001-11-20 FR FR0114988A patent/FR2832314B1/fr not_active Expired - Lifetime
-
2002
- 2002-11-19 EP EP02292870A patent/EP1312385B2/fr not_active Expired - Lifetime
- 2002-11-19 ES ES02292870T patent/ES2255600T5/es not_active Expired - Lifetime
- 2002-11-19 AT AT02292870T patent/ATE316803T1/de not_active IP Right Cessation
- 2002-11-19 DK DK02292870.9T patent/DK1312385T4/da active
- 2002-11-19 DE DE60208989T patent/DE60208989T3/de not_active Expired - Lifetime
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5001009A (en) * | 1987-09-02 | 1991-03-19 | Sterilization Technical Services, Inc. | Lubricious hydrophilic composite coated on substrates |
US5509899A (en) * | 1994-09-22 | 1996-04-23 | Boston Scientific Corp. | Medical device with lubricious coating |
WO1996030277A1 (fr) * | 1995-03-29 | 1996-10-03 | Coloplast A/S | Applicateur et procede permettant une introduction sterile d'un catheter medical |
EP0815037B1 (fr) * | 1995-03-29 | 1999-06-02 | Coloplast A/S | Applicateur et procede permettant une introduction sterile d'un catheter medical |
WO1998011932A1 (fr) * | 1996-09-18 | 1998-03-26 | Coloplast A/S | Ensemble catheter urinaire pret a l'emploi |
US5800412A (en) * | 1996-10-10 | 1998-09-01 | Sts Biopolymers, Inc. | Hydrophilic coatings with hydrating agents |
WO1998019729A1 (fr) * | 1996-11-01 | 1998-05-14 | Coloplast A/S | Ensemble sonde urinaire muni d'une sonde prete a l'emploi |
EP0935478B1 (fr) * | 1996-11-01 | 2000-01-12 | Coloplast A/S | Ensemble sonde urinaire muni d'une sonde prete a l'emploi |
GB2319507A (en) * | 1996-11-21 | 1998-05-27 | Rusch Manufacturing | Packaged catheter with lubricant-activating liquid |
WO2000067816A1 (fr) * | 1999-05-07 | 2000-11-16 | Scimed Life Systems, Inc. | Revetement lubrifiant comprenant un agent anti-adherent pour appareils medicaux |
WO2000071181A1 (fr) * | 1999-05-21 | 2000-11-30 | Scimed Life Systems, Inc. | Revetement lubrifiant pour instruments medicaux |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11167107B2 (en) | 2016-09-27 | 2021-11-09 | Coloplast A/S | Hydrated catheter with sleeve |
US11998705B2 (en) | 2016-09-27 | 2024-06-04 | Coloplast A/S | Urinary catheter assembly having a urinary catheter sealed inside of a closed package |
EP3570899B1 (fr) | 2017-01-20 | 2021-03-10 | Hollister Incorporated | Procédés de stérilisation d'un dispositif médical à revêtement hydrophile |
CN111163816A (zh) * | 2017-05-19 | 2020-05-15 | 珀雷克斯公司 | 具有亲水性烧结多孔塑料或亲水性多孔纤维空气阻止过滤器的输注装置 |
CN111163816B (zh) * | 2017-05-19 | 2022-06-21 | 珀雷克斯公司 | 具有亲水性烧结多孔塑料或亲水性多孔纤维空气阻止过滤器的输注装置 |
US11766525B2 (en) | 2017-05-19 | 2023-09-26 | Porex Corporation | Infusion device with a hydrophilic sintered porous plastic or hydrophilic porous fiber air stop filter |
US11969558B2 (en) | 2018-07-20 | 2024-04-30 | Coloplast A/S | Intermittent urinary catheter assembly |
US11771584B2 (en) | 2018-12-20 | 2023-10-03 | Coloplast A/S | Urine collecting bag |
Also Published As
Publication number | Publication date |
---|---|
FR2832314B1 (fr) | 2005-06-24 |
DE60208989T3 (de) | 2010-04-01 |
DE60208989T2 (de) | 2006-12-07 |
DE60208989D1 (de) | 2006-04-13 |
EP1312385B1 (fr) | 2006-02-01 |
DK1312385T4 (da) | 2010-01-18 |
FR2832314A1 (fr) | 2003-05-23 |
EP1312385B2 (fr) | 2009-10-21 |
ES2255600T5 (es) | 2010-02-10 |
ATE316803T1 (de) | 2006-02-15 |
DK1312385T3 (da) | 2006-06-06 |
ES2255600T3 (es) | 2006-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5005075B2 (ja) | パッケージ内の親水性カテーテルの蒸気水和 | |
JP5033426B2 (ja) | 浸透圧増強流体付きのカテーテル・アセンブリ | |
EP1312385B1 (fr) | Dispositif medical intraluminal | |
CA3075409C (fr) | Dispositif medical hydrophile a couche amovible de barriere/regulation d'humidite | |
KR20200023607A (ko) | 증기 멸균된 카테터 어셈블리 | |
EP0057033A2 (fr) | Prothèse destinée à être insérée dans des tissus vivants, en particulier prothèse mammaire et procédé de fabrication | |
WO2009095594A2 (fr) | Prothese vasculaire impermeable et procede de preparation de ladite prothese | |
FR2550085A1 (fr) | Serviette hygienique perfectionnee |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
17P | Request for examination filed |
Effective date: 20030718 |
|
AKX | Designation fees paid |
Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20060201 Ref country code: IE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060201 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060201 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060201 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060201 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: FRENCH |
|
GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 20060320 |
|
REF | Corresponds to: |
Ref document number: 60208989 Country of ref document: DE Date of ref document: 20060413 Kind code of ref document: P |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060501 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060501 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2255600 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FD4D |
|
PLBI | Opposition filed |
Free format text: ORIGINAL CODE: 0009260 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061130 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061130 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061130 Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061130 |
|
PLAX | Notice of opposition and request to file observation + time limit sent |
Free format text: ORIGINAL CODE: EPIDOSNOBS2 |
|
PLAB | Opposition data, opponent's data or that of the opponent's representative modified |
Free format text: ORIGINAL CODE: 0009299OPPO |
|
26 | Opposition filed |
Opponent name: COLOPLAST A/S Effective date: 20061031 |
|
R26 | Opposition filed (corrected) |
Opponent name: COLOPLAST A/S Effective date: 20061031 |
|
NLR1 | Nl: opposition has been filed with the epo |
Opponent name: COLOPLAST A/S |
|
NLR1 | Nl: opposition has been filed with the epo |
Opponent name: COLOPLAST A/S |
|
PLBB | Reply of patent proprietor to notice(s) of opposition received |
Free format text: ORIGINAL CODE: EPIDOSNOBS3 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
BERE | Be: lapsed |
Owner name: B. BRAUN MEDICAL SAS Effective date: 20061130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060201 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060502 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060201 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060201 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061119 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060201 |
|
PUAH | Patent maintained in amended form |
Free format text: ORIGINAL CODE: 0009272 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: PATENT MAINTAINED AS AMENDED |
|
27A | Patent maintained in amended form |
Effective date: 20091021 |
|
AK | Designated contracting states |
Kind code of ref document: B2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: AEN Free format text: BREVET MAINTENU DANS UNE FORME MODIFIEE |
|
NLR2 | Nl: decision of opposition |
Effective date: 20091021 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T4 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: DC2A Date of ref document: 20091126 Kind code of ref document: T5 |
|
NLR3 | Nl: receipt of modified translations in the netherlands language after an opposition procedure | ||
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 15 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161119 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 16 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161119 |
|
PGRI | Patent reinstated in contracting state [announced from national office to epo] |
Ref country code: IT Effective date: 20180206 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20211130 Year of fee payment: 20 Ref country code: DK Payment date: 20211126 Year of fee payment: 20 Ref country code: NL Payment date: 20211123 Year of fee payment: 20 Ref country code: GB Payment date: 20211130 Year of fee payment: 20 Ref country code: DE Payment date: 20211123 Year of fee payment: 20 Ref country code: PT Payment date: 20211026 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20211123 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20220125 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 60208989 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EUP Expiry date: 20221119 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MK Effective date: 20221118 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20221118 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20221130 Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20221118 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20230503 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20221120 |